Related Experiment Video
Updated: Jul 14, 2026
07:10
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
Haemostasis impairment in patients with obstructive jaundice
Vassilios Papadopoulos1, Dimitrios Filippou, Evangelos Manolis
11st Department of Internal Medicine, Democritus University of Thrace Medical School, Alexandroupoli.
Journal of Gastrointestinal and Liver Diseases : JGLD
|June 27, 2007
Summary
Liver disease impairs blood clotting by affecting protein synthesis. This review details hemostasis changes in obstructive jaundice and related conditions, offering diagnostic and therapeutic insights.
Area of Science:
- Hepatology
- Hematology
- Internal Medicine
Background:
- The liver is crucial for synthesizing proteins involved in blood coagulation, anticoagulation, and fibrinolysis.
- Prolonged liver disease, including biliary obstruction and parenchymal damage, frequently leads to hemostatic abnormalities.
- Obstructive jaundice is associated with complex hemostatic disturbances, impacting patient outcomes.
Purpose of the Study:
- To review current understanding of hemostasis impairment in obstructive jaundice.
- To explore hemostatic changes in associated conditions like cirrhosis, sepsis, and various cancers.
- To provide practical guidelines for diagnosing and managing bleeding or clotting risks.
Main Methods:
- Literature review of studies on hemostasis in liver disease and obstructive jaundice.
- Analysis of pathophysiology linking cholestasis to coagulation disorders.
- Synthesis of information on diagnostic and therapeutic strategies.
Main Results:
- Obstructive jaundice significantly alters coagulation factor levels and fibrinolytic activity.
- Systemic inflammation and sepsis in cholestatic diseases exacerbate hemostatic dysfunction.
- Various benign and malignant conditions (e.g., pancreatitis, cholangiocarcinoma, hepatocellular carcinoma) present with specific hemostatic profiles.
Conclusions:
- Accurate diagnosis and management of hemostatic changes in obstructive jaundice require understanding the underlying pathophysiology.
- Multifaceted approaches are needed to address bleeding and thrombotic risks in these patients.
- Further research into targeted therapeutic interventions is warranted.
Related Concept Videos
01:25Jaundice
Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:22Portal Hypertension
Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...